Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don't combine sartans and ACE-inhibitors, says EU's CHMP

This article was originally published in Scrip

Executive Summary

The European Medicines Agency's main scientific committee, the CHMP, has advised against combining different classes of drugs that act on the renin-angiotensin system (RAS) in patients with cardiovascular problems, on the grounds that dual therapy does not increase the benefits of treatment and can increase the risk of serious cardiovascular and renal side-effects.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts